Charles River to acquire Frontage's bioanalysis and DMPK businesses for $470 million

• Charles River Laboratories will acquire Frontage’s bioanalysis and DMPK businesses in Exton, Pennsylvania, for approximately $470 million in cash.
• Performance-based payments could total another $75 million; closing is expected in the first half of 2027, subject to shareholder and regulatory approvals.
• The businesses represented approximately 40% of Frontage’s $256.7 million revenue in 2025, expanding the buyer’s clinical bioanalysis capabilities.
• A consortium with Tigermed and Dr. Song Li will take Frontage private, transferring its remaining businesses to those partners.
• The acquisition is expected to be neutral to non-GAAP earnings per share in 2027 and accretive thereafter.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261108091404) on November 09, 2026, and is solely responsible for the information contained therein.